{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000055","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.689384+00:00","generated_at":"2026-06-17T06:29:00.737487+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Caribou Biosciences gets FDA Fast Track for CB-011 CAR-T in relapsed/refractory multiple myeloma","bullets":["CB-011 is an allogeneic anti-BCMA CAR-T with immune cloaking (B2M-HLA-E transgene).","Fast Track designation enables expedited FDA review and more frequent agency interactions.","CaMMouflage Phase 1 trial enrolling at dose level 1; first patient dosed recently.","CB-011 aims to be an off-the-shelf option avoiding apheresis and long manufacturing times."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000055","json":"https://secwatch.observer/filing/0001619856-23-000055.json","markdown":"https://secwatch.observer/filing/0001619856-23-000055.md","text":"https://secwatch.observer/filing/0001619856-23-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000055/0001619856-23-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000055/crbu-20230404.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:29:00.737487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}